Acamprosate is a proven effective intervention in the treatment of alcohol dependence. However, acamprosate prevents lapses or relapses only in a minority of patients. An important question, therefore, is whether there is a specific subgroup of patients who respond particularly well to acamprosate.
To identify predictors of acamprosate efficacy. Based upon the available evidence and hypotheses about the mechanisms underlying acamprosate's effects on drinking behavior, the following variables were considered to be potential positive predictors: high physiological dependence at baseline, negative family history of alcoholism, late age-of-onset, serious anxiety symptomatology at baseline, severe craving at baseline, and female gender.
Potential predictors of acamprosate's efficacy were analyzed in a pooled analysis of data from seven randomized placebo-controlled trials involving a total of 1485 patients with alcohol dependence. Outcome is measured in terms of cumulative abstinence duration (CAD), continuous abstinence (ABST), and time to first relapse (TFR).
CAD and ABST were predicted by baseline measures of craving and anxiety, as well as by study and treatment condition. Acamprosate efficacy was not differentially associated with any of the predictor variables. Importantly, the hypotheses were rejected despite the large sample size and sufficient statistical power.
The most straight-forward clinical implication of this study is that acamprosate can be considered as a potentially effective pharmacotherapy for all patients with alcohol dependence. The effect size of acamprosate alone is, however, moderate. Some evidence indicates that the combination of acamprosate with naltrexone or disulfiram leads to substantially better outcomes.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.
"The debate around the effectiveness of disulfiram and acamprosate on long-term survival in alcohol dependence continues. Predicting who will respond best to acamprosate is difficult leading to some authors stating that 'acamprosate should be considered for everyone with alcohol dependence' . Although clinical trials have been more conservative in terms of effectiveness , routine clinical practice and economic analysis  supports the use of acamprosate when tailored to specific patients and their treatment plans. "
"However, evidence from meta-analyses has not been found in support of this (NICE, 2011a; Verheul et al., 2005) (Ia). Verheul et al. (2005) (Ia) indeed concluded that acamprosate is potentially effective for anyone with alcohol dependence. At the time of writing these guidelines, a large prospective study set up to define if there are any subgroups who respond to either acamprosate or naltrexone, 'project PREDICT' has yet to formally publish its results (Mann et al., 2009) (Ib). "
[Show abstract][Hide abstract] ABSTRACT: The British Association for Psychopharmacology guidelines for the treatment of substance abuse, harmful use, addiction and comorbidity with psychiatric disorders primarily focus on their pharmacological management. They are based explicitly on the available evidence and presented as recommendations to aid clinical decision making for practitioners alongside a detailed review of the evidence. A consensus meeting, involving experts in the treatment of these disorders, reviewed key areas and considered the strength of the evidence and clinical implications. The guidelines were drawn up after feedback from participants. The guidelines primarily cover the pharmacological management of withdrawal, short- and long-term substitution, maintenance of abstinence and prevention of complications, where appropriate, for substance abuse or harmful use or addiction as well management in pregnancy, comorbidity with psychiatric disorders and in younger and older people.
Full-text · Article · May 2012 · Journal of Psychopharmacology
"ACAMP has also been found to be preferentially effective in alcohol-dependent subjects that obtained low scores on somatic distress (Kiefer et al., 2005). However, Verheul et al. (2005) in a pooled analysis of seven European trials including 1485 patients found that ACAMP was not differentially associated with any predictor variables including physiological dependence, familial alcoholism, age-of-onset, anxiety symptomatology, severity of craving or gender. Another pooled analysis of European trials (Sass et al., 1995) similarly failed to find any predictors of efficacious response to ACAMP on any baseline characteristics. "
[Show abstract][Hide abstract] ABSTRACT: To assess which baseline characteristics of patients predict response to treatment with acamprosate (ACAMP) and naltrexone (NTX) in alcohol dependence.
Outcome data from a 12-week randomized controlled trial of NTX, ACAMP and placebo for alcohol dependence were analysed by multiple logistic regression analyses to determine the predictive effects of gender and the baseline measures of dependence severity, craving, depression, anxiety and readiness to change in addition to NTX and ACAMP treatment. Moderators of the effect of each medication on outcomes were also examined.
Relapse was predicted by the interaction terms of ACAMP and alcohol dependence severity, NTX and depression as well as NTX and the readiness to change measure Taking Steps. Abstinence was similarly predicted by the interaction term ACAMP and alcohol dependence severity.
The efficacy of NTX and ACAMP in reducing relapse or lapse is influenced by different clinical characteristics.
Full-text · Article · Oct 2010 · Alcohol and Alcoholism